Remodulin Disease Interactions
There are 7 disease interactions with Remodulin (treprostinil).
- Hepatic impairment
- Bleeding
- Diverticulosis
- Hypotension
- Liver dysfunction
- Pulmonary infections
- Renal dysfunction
Treprostinil (applies to Remodulin) hepatic impairment
Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The use of the extended-release tablet formulation of treprostinil is contraindicated in patients with severe hepatic impairment (Child Pugh Class C). There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients. It is recommended to start patients with mild hepatic impairment (Child Pugh Class A) at 0.125 mg BID with 0.125 mg BID dose increments every 3 to 4 days and to avoid use of treprostinil in patients with moderate hepatic impairment (Child Pugh Class B).
Treprostinil (applies to Remodulin) bleeding
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding Associated with Coagulation Defect
Treprostinil injection inhibits platelet aggregation and increases the risk of bleeding. Close monitoring is recommended when using this agent in patients with bleeding disorders.
Treprostinil (applies to Remodulin) diverticulosis
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diverticulitis
The tablet shell of the manufactured form of treprostinil, Orenitram does not dissolve and can lodge in the diverticulum of patients with diverticulosis. Care should be exercised when using this drug in patient with diverticulosis.
Treprostinil (applies to Remodulin) hypotension
Moderate Potential Hazard, Moderate plausibility.
Treprostinil is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with treprostinil injection may produce symptomatic hypotension. Care should be exercised when using this agent in patients at risk.
Treprostinil (applies to Remodulin) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Severe hepatic impairment (Child Pugh Class C) is a contraindication in patients taking the oral presentation of treprostinil. Treprostinil is substantially metabolized by the liver, primarily by CYP450 2C8. Treprostinil injection clearance is reduced in patients with hepatic insufficiency. In patients with mild or moderate hepatic insufficiency, decrease the initial dose of treprostinil injection to 0.625 ng/kg/min ideal body weight, and monitor closely. Treprostinil injection has not been studied in patients with severe hepatic insufficiency. It is recommended to titrate treprostinil injection slowly in patients with hepatic insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.
Treprostinil (applies to Remodulin) pulmonary infections
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment
The efficacy of treprostinil inhalant has not been established in patients with significant underlying lung disease. Patients with acute pulmonary infections should be carefully monitored to detect any worsening of lung disease and loss of drug effect.
Treprostinil (applies to Remodulin) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Treprostinil and its metabolites are excreted mainly through the urinary route. It is recommended to titrate treprostinil injection slowly in patients with renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal renal function. No dose adjustments are required in patients with renal impairment. Treprostinil is not cleared by dialysis.
Switch to professional interaction data
Remodulin drug interactions
There are 327 drug interactions with Remodulin (treprostinil).
More about Remodulin (treprostinil)
- Remodulin consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Side effects
- Dosage information
- During pregnancy
- Generic availability
- Drug class: agents for pulmonary hypertension
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Cialis
Cialis (tadalafil) increase increases blood flow to a certain area of the body and is used to treat ...
Viagra
Viagra (sildenafil) is used to treat erectile dysfunction or impotence in men. Includes Viagra side ...
Tavneos
Tavneos (avacopan) is a C5a receptor antagonist used for severe active ANCA-associated vasculitis ...
Adcirca
Adcirca is used to treat pulmonary arterial hypertension. Learn about side effects, interactions ...
Opsumit
Opsumit (macitentan) is used to treat pulmonary arterial hypertension. Includes Opsumit side ...
Revatio
Revatio (sildenafil) is used to treat pulmonary arterial hypertension. Includes Revatio side ...
Adempas
Adempas (riociguat) is used to treat pulmonary hypertension. Includes Adempas side effects ...
Macitentan
Macitentan systemic is used for pulmonary arterial hypertension
Ambrisentan
Ambrisentan systemic is used for pulmonary arterial hypertension
Sildenafil
Sildenafil is used to treat erectile dysfunction and pulmonary arterial hypertension. Includes ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.